212 related articles for article (PubMed ID: 34279805)
1. Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
Snyder S; Albertson T; Garcia J; Gitlin M; Jun MP
Adv Ther; 2021 Aug; 38(8):4541-4555. PubMed ID: 34279805
[TBL] [Abstract][Full Text] [Related]
2. Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
Snyder S; Chung KC; Jun MP; Gitlin M
Adv Ther; 2021 Sep; 38(9):4659-4674. PubMed ID: 34302277
[TBL] [Abstract][Full Text] [Related]
3. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
4. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.
Ahmed N; Shahzad M; Shippey E; Bansal R; Mushtaq MU; Mahmoudjafari Z; Faisal MS; Hoffmann M; Abdallah AO; Divine C; Hamadani M; McGuirk J; Shune L
Transplant Cell Ther; 2022 Jul; 28(7):358-364. PubMed ID: 35429662
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers.
Ahmed N; Sun F; Teigland C; Kilgore KM; Mohammadi I; Chambers J; Dieyi C; Feng C; Osborn J; Fu C; Gergis U
Transplant Cell Ther; 2024 Apr; ():. PubMed ID: 38697294
[TBL] [Abstract][Full Text] [Related]
6. Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Hoda D; Richards R; Faber EA; Deol A; Hunter BD; Weber E; DiFilippo H; Henderson-Clark T; Meaux L; Crivera C; Riccobono C; Garrett A; Jackson CC; Fowler J; Theocharous P; Stewart R; Lorden AL; Porter DL; Berger A
Future Oncol; 2022 Jun; 18(19):2415-2431. PubMed ID: 35583358
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Broder MS; Ma Q; Yan T; Zhang J; Chang E; Kuzan D; Eldjerou L
Am Health Drug Benefits; 2020; 13(5):192-199. PubMed ID: 33343819
[TBL] [Abstract][Full Text] [Related]
8. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
Chodnicki KD; Prasad S
Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
[TBL] [Abstract][Full Text] [Related]
9. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
[TBL] [Abstract][Full Text] [Related]
10. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies.
Zhu F; Wei G; Zhang M; Zhao H; Wu W; Yang L; Hu Y; Huang H
Cell Transplant; 2020; 29():963689720919434. PubMed ID: 32314613
[TBL] [Abstract][Full Text] [Related]
12. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
13. Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma.
Shahzad M; Khalid MF; Amin MK; Basharat A; Ammad-Ud-Din M; Park R; Anwar I; Faisal MS; Jaglal M
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):316-322. PubMed ID: 38342727
[TBL] [Abstract][Full Text] [Related]
14. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Hiramatsu H
Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
[TBL] [Abstract][Full Text] [Related]
15. Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design.
Fyfe R; Anstis O; Kapadia K; Jordan M; Sword DO; Weinkove R
BMJ Open; 2024 Jan; 14(1):e071112. PubMed ID: 38262637
[TBL] [Abstract][Full Text] [Related]
16. Oncology nurse competency in chimeric antigen receptor T-cell therapy: A qualitative study.
He J; Li J; Feng LN; Feng LX; Qiang W; Wang W; Dong L
Nurse Educ Today; 2024 Jan; 132():106040. PubMed ID: 37956569
[TBL] [Abstract][Full Text] [Related]
17. Multidimensional Results and Reflections on CAR-T: The Italian Evidence.
Foglia E; Garagiola E; Ladisa V; Rambaldi A; Cairoli R; Sammassimo S; Salè EO; Zinzani PL; Esposti M; Alberti L; Mulas MF; Melis E; Onnis S; Marcias M; Satta V; Croce D
Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36900841
[TBL] [Abstract][Full Text] [Related]
18. [Economics and management of CAR T- cell therapy : Status quo and future perspectives].
Kron F; Franz J; Kron A; Hallek M
Internist (Berl); 2021 Jun; 62(6):620-626. PubMed ID: 33944969
[TBL] [Abstract][Full Text] [Related]
19. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
[No Abstract] [Full Text] [Related]
20. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
